Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
144
datasets available to search
ShareScore release 0.9.0
Dataset results
144 results for “anti-VEGF”
Head to Head Study of Anti-VEGF Treatment.
ClinicalTrials.gov study NCT02577107. IPD Sharing: UNDECIDED. Countries: 1. Publications: 0.
Macular Function During Anti-VEGF Treatment
ClinicalTrials.gov study NCT01023971. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Genetics in Non-response to Anti-VEGF Treatment in Exudative AMD
ClinicalTrials.gov study NCT01213667. IPD Sharing: Not stated. Countries: 1. Publications: 3.
Efficacy and Safety of Two Regimens of Anti-VEGF Therapy in Chinese Patients With Polypoidal Choroidal Vasculopathy
ClinicalTrials.gov study NCT04380974. IPD Sharing: UNDECIDED. Countries: 1. Publications: 13.
Ziv-aflibercept in Ocular Disease Requiring Anti-VEGF Injection
ClinicalTrials.gov study NCT02486484. IPD Sharing: YES. Countries: 1. Publications: 5.
Home- vs Hospital-based Care of Anti-VEGF Treatment for Diabetic Macular Edema: Non-inferiority RCT
ClinicalTrials.gov study NCT06610747. IPD Sharing: NO. Countries: 1. Publications: 12.
Anti-VEGF Therapy for Subfoveal Hemorrhage in Patients With Neovascular Age-Related Macular Degeneration
ClinicalTrials.gov study NCT03699618. IPD Sharing: NO. Countries: 1. Publications: 7.
A Study to Evaluate the Efficacy and Safety of Sintilimab in Combination With IBI305 (Anti-VEGF Monoclonal Antibody) Compared to Sorafenib as the First-Line Treatment for Advanced Hepatocellular Carci
ClinicalTrials.gov study NCT03794440. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Endophthalmitis After Intravitreous Anti-VEGF Injections in Patients Receiving vs. Not Receiving Topical Antibiotics
ClinicalTrials.gov study NCT02810587. IPD Sharing: NO. Countries: 1. Publications: 5.
Microinvasive Pars Plana Vitrectomy Combined ILM Peeling Versus Anti-VEGF Intravitreal Injection for Treatment-naïve Diabetic Macular Edema
ClinicalTrials.gov study NCT05728476. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Pharmacogenomic Study on Anti-VEGF Medicine in Treatment of Macular Neovascular Diseases
ClinicalTrials.gov study NCT03128463. IPD Sharing: NO. Countries: 1. Publications: 6.
Anti-PD-1/PD-L1 Antibodies Plus Anti-VEGF Antibody Treatment in Patients With Advanced-Stage HCC
ClinicalTrials.gov study NCT06537908. IPD Sharing: Not stated. Countries: 1. Publications: 3.
Functional and Anatomical Outcomes of Dexamethasone Intra-vitreal Implant in Patients with Resistant Macular Edema Secondary to Retinal Vein Occlusion After Intravitreal Anti-VEGF Injection
ClinicalTrials.gov study NCT05003258. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Macular Perfusion Changes After Anti-VEGF Versus Targeted Retinal Photocoagulation in Proliferative Diabetic Retinopathy
ClinicalTrials.gov study NCT04674254. IPD Sharing: NO. Countries: 1. Publications: 21.
Cryoapplication Versus Anti-VEGF Before Diabetic Vitrectomy
ClinicalTrials.gov study NCT05514925. IPD Sharing: NO. Countries: 1. Publications: 3.
Rubeosis Anti-VEGF (RAVE) Trial for Ischemic Central Retinal Vein Occlusion
ClinicalTrials.gov study NCT00406471. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Evaluation of Dry Eye Disease's Signs in Patients Who Were Administered Intravitreal Anti-VEGF Injections
ClinicalTrials.gov study NCT06317922. IPD Sharing: Not stated. Countries: 1. Publications: 5.
ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC
ClinicalTrials.gov study NCT07157969. IPD Sharing: NO. Countries: 1. Publications: 1.
Anti-vegf therapy in diabetic macular oedema patients over four years
<p>OBJECTIVES: To evaluate visual acuity (VA) outcomes of intravitreal anti-vascular endothelial growth factor (VEGF) in diabetic macular oedema (DMO).</p> <p>METHODS: In this retrospective cohort study, electronic medical records for all patients undergoing intravitreal injections (IVI) in a tertiary referral centre between March 2013 and October 2018 were analysed. Treatment response in terms of visual acuity outcomes were reported for all eyes over a 4-year observation period.</p> <p>RESULTS: Our cohort includes 2614 DMO eyes of 1964 patients over 48 months. Cox proportional hazards modelling identified injection number (hazard ratio [HR] = 1.18), male gender (HR = 1.13), and baseline VA (HR = 1.09) as independent predictors to reach a favourable visual outcome of more than 70 Early Treatment Diabetic Retinopathy Study (ETDRS) letters. Half of our cohort reached 70 letters 1.9 months after starting anti-VEGF therapy. Of those that reached 70 letters, 50% fell below 70 by 14.7 months.</p> <p>CONCLUSION: To date, this is the largest single centre cohort study and over the longest observation period reporting on real-life outcomes of anti-VEGF in DMO. We have made an anonymised version of our dataset available on an open-source data repository as a resource for clinical researchers globally.</p>
Insights from survival analyses during 12 years of anti-VEGF therapy for neovascular age-related macular degeneration
<p><b>Importance</b>: While multiple imputation models for missing data and use of mixed effects models generally provide better outcome estimates than using only observed data or last observation carried forward in clinical trials, such approaches usually cannot be applied to visual outcomes from retrospective analyses of clinical practice settings, so-called real-world outcomes.</p> <p><b>Objective: </b>To<b> </b>explore potential utility of survival analysis techniques for retrospective clinical practice visual outcomes.</p> <p><b>Design</b>: Retrospective cohort study with 12-year observation period.</p> <p><b>Setting: </b>A tertiary eye center.</p> <p><b>Participants</b>: Of 10,744 eyes with neovascular AMD receiving anti-VEGF therapy between October 2008 and February 2020, 7802 eyes met study criteria (treatment-naïve, first-treated eyes starting anti-VEGF therapy).</p> <p><b>Main outcome measures</b>: Kaplan-Meier estimates and Cox proportional hazards modelling were used to consider: VA reaching ETDRS (Early Treatment Diabetic Retinopathy Study) letter score 70 (Snellen equivalent 20/40) or better; duration VA sustained at or better than 70 (20/40); and VA declining to 35 (20/200) or worse.</p> <p><b>Results</b>: The median time to attaining VA letter score ≥ 70 (20/40) was 2.0 years (95% CI 1.87 - 2.32) after the first anti-VEGF injection. Predictive features were baseline VA (HR 1.43 per 5 ETDRS letter score or 1 line [95% CI 1.40 - 1.46]), baseline age (HR 0.88 per 5 years [95% CI 0.86 - 0.90]), and injection number (HR 1.123 [95% CI 1.101 - 1.15]). Of the 56% attaining this outcome, median time sustained at 70 (20/40) or better was 1.1 years (95% CI 1.1 - 1.2).</p> <p><b>Conclusions and relevance</b>: Survival analysis potentially addresses key limitations of retrospective clinical practice (real-world) data by accounting for variable observation time-points and follow-up durations. Modelling with multiple covariates reveals factors that may help inform the likely visual trajectory of an individual. We demonstrate the utility of our proposed analyses by showing that patients with neovascular AMD beginning anti-VEGF therapy are more likely to experience positive visual outcomes within the first 2.9 years, typically maintaining this for 1.1 years, but then deteriorating to poor vision within 8.7 years. We believe that this dataset, combined with our statistical approach for retrospective analyses, may provide long-term prognostic information for patients newly diagnosed with this condition.<a name="_nckpxvmwyi"></a></p>
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.